Clinical studies have demonstrated that Empliciti, in combination with other drugs like lenalidomide and dexamethasone, significantly improves progression-free survival compared to lenalidomide and dexamethasone alone. The addition of Empliciti has been shown to enhance the overall response rate and extend the duration of remission in patients with multiple myeloma.
